Michael Livecchi
About Michael Livecchi
Michael Livecchi is the Senior Director of Corporate Financial Planning & Analysis at Bristol Myers Squibb, with over 20 years of experience in financial planning and analysis, primarily in the pharmaceutical industry.
Company
Michael Livecchi currently works at Bristol Myers Squibb, a prominent global pharmaceutical company. He has held multiple key positions at this organization, demonstrating a longstanding tenure and significant expertise in financial planning and analysis within the pharmaceutical industry. His roles have spanned various departments, including corporate financial planning, pricing, reimbursement, and cardiovascular finance.
Title
Michael Livecchi is the Senior Director of Corporate Financial Planning & Analysis at Bristol Myers Squibb. This role involves overseeing financial strategies, planning, and analysis, contributing to the financial health and strategic direction of the company.
Career at Bristol Myers Squibb
Michael Livecchi's extensive career at Bristol Myers Squibb began in 2002. He has held several important positions, including Internal Auditor, Internal Controls Manager (SOX), Associate Finance Director US Reporting & Analysis, Associate Finance Director Diabetes, Finance Director Diabetes, Head of U.S. Cardiovascular Finance, Director Pricing and Reimbursement, and most recently, Senior Director Corporate Financial Planning & Analysis. His roles have been pivotal in managing financial planning and strategic financial initiatives across various segments of the company.
Experience at AstraZeneca
Michael Livecchi also gained valuable experience at AstraZeneca, where he served as the Director of Financial Planning & Analysis for the Diabetes sector from 2014 to 2015. During his tenure, he focused on optimizing financial strategies for the company’s diabetes portfolio, leveraging his extensive expertise in the pharmaceutical industry.
Educational Background
Michael Livecchi studied at the University at Albany, SUNY, where he earned a Bachelor of Science (BS) degree. His education has been a solid foundation for his extensive 20-year career in financial planning and analysis, particularly in the pharmaceutical industry.